uniQure N.V.
$17.78
97
+$0.33+1.89% Today
Statistics
Day High
18.11
Day Low
17.44
52W High
70.59
52W Low
9.03
Volume
471,452
Avg. Volume
-
Mkt Cap
1.11B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
12MayExpected
Expected EPS
-0.867992
Actual EPS
N/A
Financials
-1,236%Profit Margin
Unprofitable32.2MRevenue
-397.94MNet Income
Analyst Ratings
37.5Average Price Target
The highest estimate is 70.00.
From 12 ratings within the last 6 months. This is not an investment recommendation.
From 12 ratings within the last 6 months. This is not an investment recommendation.
Buy 58%
Hold 42%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow QURE. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Sangamo Therapeutics
SGMO
Mkt Cap108.54M
Biomarin Pharmaceutical
BMRN
Mkt Cap10.51B
Pfizer
PFE
Mkt Cap156.77B
Regenxbio
RGNX
Mkt Cap489.85M
Sarepta Therapeutics
SRPT
Mkt Cap2.26B
Intellia Therapeutics
NTLA
Mkt Cap1.77B
CRISPR Therapeutics
CRSP
Mkt Cap5.57B
About
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Show more...
CEO
Mr. Matthew Craig Kapusta CPA
Employees
209
Country
Netherlands
ISIN
NL0010696654
Listings
0 Comments
Share your thoughts
FAQ
What is uniQure N.V. stock price today?▼
The current price of QURE is $17.78 USD — it has increased by +1.89% in the past 24 hours. Watch uniQure N.V. stock price performance more closely on the chart.
What is uniQure N.V. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange uniQure N.V. stocks are traded under the ticker QURE.
Is uniQure N.V. stock price growing?▼
QURE stock has risen by +3.41% compared to the previous week, the month change is a +10.5% rise, over the last year uniQure N.V. has showed a +23.56% increase.
What is uniQure N.V. market cap?▼
Today uniQure N.V. has the market capitalization of 1.11B
When is the next uniQure N.V. earnings date?▼
uniQure N.V. is going to release the next earnings report on May 12, 2026.
What were uniQure N.V. earnings last quarter?▼
QURE earnings for the last quarter are -0.57 USD per share, whereas the estimation was -0.91 USD resulting in a +37.63% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is uniQure N.V. revenue for the last year?▼
uniQure N.V. revenue for the last year amounts to 32.2M USD.
What is uniQure N.V. net income for the last year?▼
QURE net income for the last year is -397.94M USD.
How many employees does uniQure N.V. have?▼
As of April 22, 2026, the company has 209 employees.
In which sector is uniQure N.V. located?▼
uniQure N.V. operates in the Health & Wellness sector.
When did uniQure N.V. complete a stock split?▼
uniQure N.V. has not had any recent stock splits.
Where is uniQure N.V. headquartered?▼
uniQure N.V. is headquartered in Amsterdam, Netherlands.